Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGRIT: Astuprotimut-r in Resected MAGE-A3+ NSCLC
NCT00480025Phase 3Terminated
- Sponsor
- GSK
- Start
- Oct 2007
- Primary completion
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics, Peptides, Fc-Fusion Proteins
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial of astuprotimut-R in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: Disease-free Survival up to 5 years. Started Oct 2007; status: terminated.
02
Drugs
astuprotimut-R
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00480025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480025.